Chronic kidney disease Trials in Miami Lakes, United States
Conditions / Chronic kidney disease / Miami Lakes, United States
Chronic kidney disease has been the subject of sustained clinical investigation across multiple research sites.
11 total trials for this combination
Showing top 10 of 11 trials
Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT06926660 | A Study to Test Whether Vicadrostat in Combination With Empagliflozin Helps People With Chronic Kidney Disease | ACTIVE_NOT_RECRUITING | — |
| NCT05013008 | An add-on Study to the FIGARO-DKD Study Called FIGARO-BM to Learn About the Link Between Biomarkers (Substances in the Blood Used as Indicators of Biological Processes, Disease Processes or Responses to Medication) and Finerenone in FIGARO-DKD Participants | COMPLETED | PHASE2 |
| NCT02940860 | Iron Isomaltoside/Ferric Derisomaltose vs Iron Sucrose for Treatment of Iron Deficiency Anemia in Non-Dialysis-Dependent Chronic Kidney Disease | COMPLETED | PHASE3 |
| NCT03036150 | A Study to Evaluate the Effect of Dapagliflozin on Renal Outcomes and Cardiovascular Mortality in Patients With Chronic Kidney Disease | COMPLETED | PHASE3 |
| NCT03710291 | Evaluation of Effect of TRC101 on Progression of Chronic Kidney Disease in Subjects With Metabolic Acidosis | TERMINATED | PHASE3 |
| NCT03990363 | A Study of Verinurad and Allopurinol in Patients With Chronic Kidney Disease and Hyperuricaemia | COMPLETED | PHASE2 |
| NCT05021835 | ZEUS - A Research Study to Look at How Ziltivekimab Works Compared to Placebo in People With Cardiovascular Disease, Chronic Kidney Disease and Inflammation | ACTIVE_NOT_RECRUITING | PHASE3 |
| NCT02540993 | Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease | COMPLETED | PHASE3 |
| NCT04736628 | A Study to Test the Effect of Different Doses of Avenciguat (BI 685509) on Kidney Function in People With Chronic Kidney Disease | COMPLETED | PHASE2 |
| NCT05803421 | A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk | COMPLETED | — |